id: antiviral_treatment_access_to_hcc_treatment_outcomes
name: Access to Adjuvant Antiviral Treatment â†’ Hepatocellular Carcinoma Treatment
  Outcomes
from_node:
  node_id: antiviral_treatment_access
  node_name: Access to Adjuvant Antiviral Treatment
to_node:
  node_id: hcc_treatment_outcomes
  node_name: Hepatocellular Carcinoma Treatment Outcomes
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Viral etiology (predominantly hepatitis B and C) drives hepatocellular
  carcinoma development in the study populations'
- 'Step 2: Adjuvant antiviral treatment can reduce viral load and hepatic inflammation,
  potentially improving liver function and reducing recurrence risk'
- 'Step 3: Absence of reporting on antiviral treatment access suggests unmeasured
  structural variation in comprehensive HCC care'
- 'Step 4: Healthcare system integration determines whether patients receive both
  cancer treatment and underlying viral disease management'
evidence:
  quality_rating: C
  n_studies: 18
  primary_citation: 'Avik Majumdar et al. 2017. "Management of people with early-
    or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.."
    *The Cochrane database of systematic reviews*. https://doi.org/10.1002/14651858.CD011650.pub2'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.641211'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: healthcare_system_integration
  direction: strengthens
  strength: strong
  description: Integrated care systems that coordinate cancer treatment with viral
    hepatitis management likely improve outcomes through comprehensive disease control
- name: antiviral_medication_cost
  direction: weakens
  strength: strong
  description: High cost of antiviral medications creates economic barriers to adjuvant
    treatment, particularly in low-resource settings
